Clinical Trials Logo

Anaplastic Lymphoma Kinase clinical trials

View clinical trials related to Anaplastic Lymphoma Kinase.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04887519 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

Start date: December 30, 2020
Phase:
Study type: Observational

The aims of the study are to assess the safety profile of brigatinib and the clinical response rates in adults with Anaplastic Lymphoma Kinase (ALK)-Positive Metastatic Non Small Cell Lung Cancer (NSCLC). Treatment with brigatinib and follow-up will be according to routine clinical practice. Study doctors will review the participants' medical records at the start of the study, then at 12 and 24 weeks after treatment starts.